PUBLISHER: The Insight Partners | PRODUCT CODE: 1226914
PUBLISHER: The Insight Partners | PRODUCT CODE: 1226914
The Asia Pacific pharmaceutical excipients market is expected to grow from US$ 1,143.55 million in 2022 to US$ 1,856.35 million by 2028. It is estimated to register a CAGR of 8.4% from 2022 to 2028.
Use of Nanotechnology to Improve Excipient Capabilities is fueling the growth of Asia Pacific pharmaceutical excipients market
Nano-delivery systems and nanomedicine are new and rapidly growing fields where nanoscale materials are used to deliver therapeutic agents to targeted sites or as diagnostic tools. Nanotechnology provides several advantages in treating chronic human diseases through site-specific and selective delivery of accurate medicines. The application of nanotechnology for the prevention and treatment of diseases has created a broad forum for the distribution of difficult-to-deliver active pharmaceutical ingredients. The increased use of nanotechnology-assisted drug delivery systems (NADDS) has shown many benefits, from enhancing oral bioavailability to targeting drugs to particular tissues. NADDS face challenges in their production and manufacture. Many excipients are used to prevent aggregation during processing and to achieve nanoscale size. Nano-excipients are manufactured deliberately or generated unintentionally during the manufacturing of NADDS. During the manufacturing of NADDS, the process has the potential to convert the excipients into nano-excipients. Nano-excipients have enhanced properties compared to excipients. Nano-excipients are easily transported through biological membranes. Also, they can easily get absorbed into the blood and delivered to the targeted tissue and cell. Nano-excipients stay in the circulatory system for a prolonged period and release the amalgamated drugs as per the specified dose. The efficient production of NADDS includes a detailed understanding of the physicochemical properties and functionality of the excipients. Thus, nanotechnology excipients will witness intensive scientific investigations in the coming years, as they can contribute unique functionality to drug products. This increase in the use of nanotechnology for the development of nano-excipients and pharmaceutical drug production is responsible for the growth of the Asia Pacific pharmaceutical excipients market.
Asia Pacific Pharmaceutical Excipients Market Overview
Asia Pacific was the fastest-growing region of the global pharmaceutical excipients market in 2021 due to the rising interest of major players in developing countries and the increasing number of key players willing to outsource their excipients manufacturing activities to low manufacturing and labor costs. The growing population in countries such as China and India is likely to increase the demand for pharmaceutical excipients in the region. China has launched over 500 types of pharmaceutical excipients. According to the World Health Organization, about 400 pharmaceutical excipient manufacturers are in China, over 23% of which specialize in producing pharmaceutical excipients, while the remaining focus on chemical or food processing. Currently, leading foreign pharmaceutical excipient companies, such as Colorcon (US), Meggle (Germany), Degussa (Germany), and Roquette (France), have established joint ventures, wholly owned companies, or offices in China. Colorcon provides film-coated products, Roquette pharmaceutical provides starch, and Meggle primarily provides pharmaceutical lactose and polyols. Chinese pharmaceutical excipient giants include Sunhere Pharmaceutical Excipients, Er-Kang Pharmaceuticals, Dongbao Bio-Tech, Zhanwang Pharmaceutical, Qinghai Gelatin, Shandong Liaocheng A Hua Pharmaceutical, and Qufu Tianli. Still, their market concentration rate is relatively low.
Asia Pacific Pharmaceutical Excipients Market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Pharmaceutical Excipients Market Segmentation
The Asia Pacific pharmaceutical excipients market is segmented into type, clinical indication, functionality, application, end user, and country. Based on type, the Asia Pacific pharmaceutical excipients market is segmented into bioresorbable polymers & lipids & liposome-based formulation, oleochemicals, sugars, cellulose, starches, petrochemicals, plant protein & polyols & cyclodextrins, inorganic chemicals, and others. The inorganic chemicals segment registered the largest market share in 2022.
Based on clinical indication, the Asia Pacific pharmaceutical excipients market is segmented into cancer, metabolic, infectious diseases, dental, ophthalmic, gene therapies, and others. The cancer segment registered the largest market share in 2022.
Based on functionality, the Asia Pacific pharmaceutical excipients market is segmented into coloring agent & coating agents, sweetener & flavoring agents, suspending & viscosity agents, preservative & controlled-release, antioxidant & oil, tablet filler & diluents, binders & compression aids & granulating agents, emulsifiers, and others. The tablet filler and diluents segment registered the largest market share in 2022.
Based on application, the Asia Pacific pharmaceutical excipients market is segmented into parenteral, orals formulations & tablets, capsules, liquid & injectable, physicochemical excipient container interactions in prefilled syringes, nutraceuticals & OTC, topical, and others. The orals formulations & tablets segment registered the largest market share in 2022.
Based on end user, the Asia Pacific pharmaceutical excipients market is segmented into biopharma industries, pharma industries, animal health, and others. The pharma industries segment registered the largest market share in 2022.
Based on country, the Asia Pacific pharmaceutical excipients market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the market in 2022.
Archer-Daniels-Midland Co, AshLand Inc, Avantor Inc, BASF SE, Evonik Industries AG, JRS PHARMA GmbH & Co. KG, MEGGLE GmbH & Co KG, Roquette Freres SA, The Dow Chemical Co, and The Lubrizol Corp are among the leading companies operating in the Asia Pacific pharmaceutical excipients market.